Anti-BCL11A [BCL11A/123]

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: Anti-BCL11A [BCL11A/123]
• Research fields: Cancer;Genetics;Neurobiology
• Clone: BCL11A/123
• Tool sub type: Primary antibody
• Class: Monoclonal
• Conjugation: Unconjugated
• Molecular weight: Predicted 91 kDa
• Reactivity: Human ; Rat
• Host: Mouse
• Application: IHC ; IP ; WB
• Description: The BCL11A/123 antibody specifically recognises the extra long form of the protein and not the long or short forms of BCL11A. The BCL11A/123 antibody is not cross reactive with the long form of the BCL11B protein that shares significant sequence identity with the immunogen.
• Immunogen: C-terminus of extra long isoform of BCL11A, BCL11AXL (aa 637-835)
• Isotype: IgG1
• Myeloma used: P3/NS1/1-Ag4.1
• Recommended controls: Tonsil (in B cells and plasmcytoid dendritic cells), Neurones and nuclei of some epithelium

Target Details

• Target: BCL11A (EVI9, CTIP1)
• Molecular weight: Predicted 91 kDa
• Tissue cell line specificity: Tonsil (in B cells and plasmcytoid dendritic cells), Neurones and nuclei of some epithelium
• Target background: BCL11A is a KrĂźppel zinc-finger transcription factor that was identified originally from a chromosome translocation in aggressive B-cell chronic lymphocytic leukaemia. The gene may function as both an oncogene and a tumour suppressor. Alternative splicing generates multiple isoforms, the BCL11AXL being the largest and most abundant transcript. The protein is differentially expressed during B-cell development and is strongly expressed in plasmacytoid dendritic cells.

Applications

• Application: IHC ; IP ; WB

Handling

• Format: Liquid
• Concentration: 1 mg/ml
• Unit size: 100 ug
• Storage buffer: PBS with 0.02% azide
• Storage conditions: -15° C to -25° C
• Shipping conditions: Shipping at 4° C

References

• Chetaille et al. 2009. Blood. 113(12):2765-3775. PMID: 19096012.
• Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome.
• Marafioti et al. 2008. Blood. 111(7):3778-92. PMID: 18218851.
• Novel markers of normal and neoplastic human plasmacytoid dendritic cells.
• Weniger et al. 2006. Leukemia. 20(10):1880-2. PMID: 16871282.
• Pulford et al. 2006. Leukemia. 20(8):1439-41. PMID: 16710303.
• Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in primary mediastinal B-cell lymphoma.
• The BCL11AXL transcription factor: its distribution in normal and malignant tissues and use as a marker for plasmacytoid dendritic cells.
• Liu et al. 2006. Mol Cancer. 5:18. PMID: 16704730.
• Fn studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells.